Despite a decision last week by Idenix Pharmaceuticals Inc. to reduce dosing levels to avoid gastrointestinal side effects of its hepatitis C Phase IIb drug candidate, NM283 - a move that drove the company’s stock down by 28.3 percent - partner Novartis AG exercised its option to license the product anyway in a deal worth up to $525 million. (BioWorld Today) Read More
